by Kelley Tracy | Jan 1, 2023 | Uncategorized
Fox Chase Chemical Diversity Center Announces it is Changing its Name to Fox Chase Therapeutics Discovery Inc Doylestown, PA. January 1, 2023 – Fox Chase Chemical Diversity Center, Inc. is changing its name to Fox Chase Therapeutics Discovery, Inc. to reflect a...
by Kelley Tracy | Aug 24, 2022 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Licensed a Platform to VeraDermics, Inc. for the Treatment of Molluscum Contagiosum and Related Pox-Virus Diseases Doylestown, PA. August 24, 2022 – FCCDC is pleased to announce that a small-molecule...
by Kelley Tracy | Jun 21, 2022 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II STTR Entitled “Optimizing a Stapled-Peptide that Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis” (R42AI170552) Doylestown, PA. June 21, 2022 – FCCDC is pleased to...
by Kelley Tracy | Apr 27, 2022 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it is Licensing to Basilea Pharmaceutica, Ltd. a Broad Spectrum Anti-Fungal Platform Technology Doylestown, PA. April 27, 2022 – FCCDC is pleased to announce that FCCDC is licensing to Basilea Pharmaceutica, Ltd....
by Kelley Tracy | Jun 25, 2021 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded an NIH Grant from the National Institution of Aging Entitled “Therapeutics Targeting TDP-43 to Treat Alzheimer’s Disease and Related Disorders” Doylestown, PA. June 25, 2021...
by Kelley Tracy | Apr 20, 2021 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant Entitled “Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum” Doylestown, PA. April 20, 2021...
